- Home
- CNF vs ACRV Comparison
CNF vs ACRV Comparison
Compare CNF & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- ACRV
- Stock Information
- Founded
- CNF 1999
- ACRV 2018
- Country
- CNF China
- ACRV United States
- Employees
- CNF N/A
- ACRV N/A
- Industry
- CNF Finance: Consumer Services
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- CNF Finance
- ACRV Health Care
- Exchange
- CNF Nasdaq
- ACRV Nasdaq
- Market Cap
- CNF 35.7M
- ACRV 41.7M
- IPO Year
- CNF 2018
- ACRV 2022
- Fundamental
- Price
- CNF $0.67
- ACRV $1.24
- Analyst Decision
- CNF
- ACRV Buy
- Analyst Count
- CNF 0
- ACRV 7
- Target Price
- CNF N/A
- ACRV $17.60
- AVG Volume (30 Days)
- CNF 189.4K
- ACRV 264.8K
- Earning Date
- CNF 08-27-2025
- ACRV 08-19-2025
- Dividend Yield
- CNF N/A
- ACRV N/A
- EPS Growth
- CNF N/A
- ACRV N/A
- EPS
- CNF 0.08
- ACRV N/A
- Revenue
- CNF $85,661,735.00
- ACRV N/A
- Revenue This Year
- CNF $252.34
- ACRV N/A
- Revenue Next Year
- CNF N/A
- ACRV $1,037.93
- P/E Ratio
- CNF $9.80
- ACRV N/A
- Revenue Growth
- CNF N/A
- ACRV N/A
- 52 Week Low
- CNF $0.37
- ACRV $1.05
- 52 Week High
- CNF $2.84
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- CNF 44.28
- ACRV 41.97
- Support Level
- CNF $0.68
- ACRV $1.21
- Resistance Level
- CNF $0.88
- ACRV $1.32
- Average True Range (ATR)
- CNF 0.08
- ACRV 0.10
- MACD
- CNF -0.01
- ACRV -0.01
- Stochastic Oscillator
- CNF 1.92
- ACRV 10.34
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.